JB CALLABLE MULTI BARRIER REVERSE CONVERTIBLE - BIOMARIN PHARMACEUTICAL/BIOGEN IDEC/AMGEN/MODERNA

JB CALLABLE MULTI BARRIER REVERSE CONVERTIBLE - BIOMARIN PHARMACEUTICAL/BIOGEN IDEC/AMGEN/MODERNA Share Price

Certificat

MBLDJB

CH1269061482

Market Closed - Swiss Exchange 08:50:00 03/05/2024 pm IST
100.2 ^CHF	+0.05%

Current month	+0.60%
1 month	+1.83%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Chart JB CALLABLE MULTI BARRIER REVERSE CONVERTIBLE - BIOMARIN PHARMACEUTICAL/BIOGEN IDEC/AMGEN/MODERNA

Latest news about AMGEN INC.

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	29/05	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	29/05	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	28/05	RE
Supreme Court Holds Invalid Cholesterol Drug Patent That Covered Millions Of Undisclosed Antibodies	27/05	AQ

More news

Static data

Product type	Reverse Convertibles
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Bank Julius Bär
	MBLDJB
ISIN	CH1269061482
Date issued	23/08/2023
Strike	257.4 $
Maturity	23/08/2024 (86 Days)
Parity	0.26 : 1
Emission price	100 CHF
Emission volume	N/A
Settlement	both
Currency	CHF

Technical Indicators

Highest since issue	100.2 CHF
Lowest since issue	80.7 CHF
Spread	5 CHF
Spread %	0.50%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company